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Abstract
Background: In vitro and in vivo resistance of Plasmodium falciparum to atovaquone or atovaquone-
proguanil hydrochloride combination has been associated to two point mutations in the parasite
cytochrome b (cytb) gene (Tyr268Ser and Tyr268Asn). However, little is known about the prevalence of
codon-268 mutations in natural populations of P. falciparum without previous exposure to the drug in
Africa.
Methods: The prevalence of codon-268 mutations in the cytb gene of African P. falciparum isolates from
Nigeria, Malawi and Senegal, where atovaquone-proguanil has not been introduced for treatment of
malaria was assessed. Genotyping of the cytb gene in isolates of P. falciparum was performed by PCR-
restriction fragment length polymorphism and confirmed by sequencing.
Results: 295 samples from Nigeria (111), Malawi (91) and Senegal (93) were successfully analyzed for
detection of either mutant Tyr268Ser or Tyr268Asn. No case of Ser268 or Asn268 was detected in cytb
gene of parasites from Malawi or Senegal. However, Asn268 was detected in five out of 111 (4.5%)
unexposed P. falciparum isolates from Nigeria. In addition, one out of these five mutant Asn268 isolates
showed an additional cytb mutation leading to a Pro266Thr substitution inside the ubiquinone reduction
site.
Conclusion: No Tyr268Ser mutation is found in cytb of P. falciparum isolates from Nigeria, Malawi or
Senegal. This study reports for the first time cytb Tyr268Asn mutation in unexposed P. falciparum isolates
from Nigeria. The emergence in Africa of P. falciparum isolates with cytb Tyr268Asn mutation is a matter
of serious concern. Continuous monitoring of atovaquone-proguanil resistant P. falciparum in Africa is
warranted for the rational use of this new antimalarial drug, especially in non-immune travelers.
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Background
The rapid development and spread of drug resistant Plas-
modium falciparum is a serious global health problem in
the management of malaria infections. Increasing resist-
ance to antimalarials by P. falciparum has led to renewed
search for alternative effective new drugs with unique cel-
lular targets. In the 1990s, the urgent need for new anti-
malarial drugs for treatment and chemoprophylaxis led to
the development of atovaquone (2-[trans-4-(4'-chloroph-
enyl) cyclohexyl]-3-hydroxy-1,4-hydroxynaphtoqui-
none)[1]. This anti-malarial compound has broad
spectrum activity against human protozoan pathogens
[2,3] among which are the Plasmodium  spp. [4,5].
Atovaquone is a potent and specific inhibitor of the cyto-
chrome bc1 (cytbc1) complex [6,7], an essential respira-
tory enzyme present in the inner mitochondrial
membrane. Unfortunately, in the Plasmodium genus and
especially in P. falciparum, atovaquone when used as a sin-
gle agent showed a high frequency of recrudescence [8,9]
and recrudescing parasites are approximately 1,000–
10,000 fold more resistant [10-12]. In order to minimize
the risk of resistance development, a fixed synergistic
combination of atovaquone with proguanil hydrochlo-
ride was developed under the trade name of Malarone®. It
has been suggested that proguanil at lower doses acts syn-
ergistically to enhance the ability of atovaquone to col-
lapse the mitochondrial membrane potential without
affecting electron transport inhibition [13]. However, the
exact mechanism of synergy between these two drugs
remains unknown. The combination of atovaquone-pro-
guanil (AP) can achieve a cure rate of 99%–100% [9,14-
16]. Despite its high activity against the malaria parasite,
the cost of AP treatment has until now restricted its use to
western non-immune adult and children [17] travelers
and some European military personnel [18]. Unfortu-
nately, there is growing evidence that malaria parasites
may quickly develop resistance to AP by mutation of
amino acid residues located in or near the atovaquone-
binding site on cytb [19-23]. Only a decade after its intro-
duction, AP treatment failures have been reported in non-
immune travelers returning from Africa. Nearly all cases
are from individuals who have visited West Africa.
[11,22,24-27]. AP treatment failures in a significant
number of these patients have been genetically linked to
point mutations in the atovaquone-binding site of the P.
falciparum  mitochondrial  cytb  gene(Tyr268Ser or
Tyr268Asn or Tyr268Cys) [11,12,22,24-28].
Recently, Kessl and colleagues [7] used site directed muta-
genesis in Saccharomyces cerevisiae to genetically and bio-
chemically confirm the linkage of atovaquone/AP
resistance to cytb mutations (Tyr268Ser and Tyr268Asn)
and to explain at the molecular level the mechanism of
malaria parasites resistance to this drug. Cytb Tyr268Ser
and Tyr268Asn mutations, have been used as a potential
molecular marker of AP resistance in non-immune travel-
ers who present with malaria after visiting disease
endemic areas [11,12,22,24-30].
It has been suggested that AP resistant phenotypes might
arise through strong selection of resistant sub-populations
harboring resistance associated mutations [12,29] or,
through a mutagenic capacity of atovaquone on P. falci-
parum  parasites alone or even in the AP combination
[19,20,25] However, very little is known on the back-
ground/baseline prevalence of codon-268 mutations in
natural populations of P. falciparum without previous
exposure to the drug in Africa. In this study, the preva-
lence of codon-268 mutations in the cytb gene of P. falci-
parum  isolates from Nigeria, Malawi and Senegal was
assessed.
Although, no Tyr268Ser mutation is found in cytb of P. fal-
ciparum isolates from Nigeria, Malawi or Senegal, the pres-
ence of the cytb Tyr268Asn mutation is reported for the
first time in unexposed P. falciparum isolates from Nigeria.
The emergence of cytb Tyr268Asn mutation in P. falci-
parum populations of Africa is a matter of serious concern,
since the AP combination has not been widely used yet in
West Africa.
Methods
Study areas
The studies were conducted at the Malaria Research Labo-
ratory, College of Medicine, University of Ibadan, Nigeria
(2003–2005), the Queen Elizabeth Central Hospital
(within the Blantyre Malaria Project), University of
Malawi College of Medicine, Blantyre, Malawi (1996–
2005) and the Malaria Research Laboratory, Hopital Le
Dantec, Dakar, Senegal (2002–2005).
The Human Subjects Committee of Harvard School of
Public Health in Boston, the Institutional Review Com-
mittees at the University of Ibadan, Ibadan, Nigeria, the
ethical review committee at the College of Medicine, Uni-
versity of Blantyre, Malawi and the Ethics Committee of
the Senegalese Ministry of Health approved the protocols
used in these studies. Documented informed consent was
obtained from parents/guardians.
Biological materials
Peripheral blood samples preserved on 3 MM Whatman®
filter paper were obtained from Nigerian children with
microscopically confirmed P. falciparum. Parasites DNA
samples from Nigerian patients used in this study are the
same with those reported in a previous study describing
the association between mutations in parasites dhfr and
dhps genes and in vivo sulfadoxine-pyrimethamine resist-
ance [31].Malaria Journal 2006, 5:82 http://www.malariajournal.com/content/5/1/82
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Samples from Senegal were collected from patients
attending a health clinic in Pikine, a suburb of the capital
city, Dakar. A drop of blood obtained from each study
participant at enrollment was blotted unto filter paper
(ISOCODE, Schleicher & Schuell). The samples were air
dried and stored in plastic bags containing silica gel.
In Malawi, parasite DNA was obtained from either an
archive of material collected from 1996 to 2004 or as part
of an ongoing study of genetic diversity from 2003 to the
present. Samples were collected from patients ranging
from infants through adult with a spectrum of clinical dis-
ease from asymptomatic carriage to severe disease
although this information was not used for analysis (i.e.,
the 91 samples represent the "population" of parasites for
Malawi). All samples were either exempt from consent
(archived parasite DNA previously extracted and stored at
-80°C) or consented for collection of parasite DNA (fresh
samples of peripheral blood extracted and stored at -
80°C).
DNA Extraction and PCR-RFLP for detection of codon-268 
mutations in the cytb gene
Parasite genomic DNA was extracted from blood samples
collected on filter paper using the chelex extraction
method as described by Plowe and others[32]. Part of the
DNA extracted from each sample was used immediately
for PCR and the rest was stored at -20°C. The P. falciparum
mitochondrial  cytb  gene (GenBank accession no.
M99416) was amplified by nested polymerase chain reac-
tion and analyzed by restriction fragment length polymor-
phisms (RFLP). A nested PCR was designed using Cytb1
and Cytb2 as primary amplification primers and 3 differ-
ent pairs of nested primers (Cytb2/Cytb6, Cytb2/Cytb7 and
Cytb3/Cytb5) to distinguish the 3 known polymorphisms
at codon 268 (Tyr268, Ser268 and Asn268). Primers
sequences, primary and nested PCR conditions and proce-
dures were performed as described previously by Schwo-
bel and colleagues [25]. The product of each second
round PCR was electrophoresed on 2% agarose gel and
visualized under UV transillumination following staining
with ethidium bromide.
RLFP analysis of each cytb secondary amplification prod-
uct was performed by digesting 5 μL of each PCR product
with the appropriate restriction enzyme and its buffer in a
total volume 15 μL and incubated at 37°C over night. The
result was detected by electrophoresis in ethidium bro-
mide-stained agarose gel (NuSieve® 3:1, Cambrex Bio-
science Rockland Inc, ME, USA).
For detection of the wild-type Tyr268 allele at position
268, 5 μL of the secondary amplification product using
the primer pair Cytb3/Cytb5, was mixed with 1 U of the
restriction enzyme NsiI (New England Biolabs, Beverly,
MA). The enzyme cuts the wild-type allele (Tyr268) and
mutant Asn268 but not the mutant Ser268 allele. Detec-
tion of mutant Ser268 allele was performed by digesting 5
μL of the 171 bp region amplified using the primer pair
Cytb2/Cytb2 with 1 U of the restriction enzyme AlwNI
(New England Biolabs, Beverly, MA). AlwNI  cuts the
mutant Ser268 allele but not the wild-type Tyr268 or the
mutant Asn268 allele. The mutant Asn268 allele was
detected by mixing 5 μL of the secondary amplification
product (174 bp) using Cytb2/Cytb7 with 1 U of SspI (New
England Biolabs, Beverly, MA). The enzyme cuts the wild-
type Tyr268 allele or the mutant Ser268 allele but not the
mutant Asn268 allele. DNA of P. falciparum clones 3D7
(Tyr268 allele), K1 (Tyr268 allele) and NGATV0l (Asn268
allele) strain were used as controls.
Clonal analysis of PCR products and DNA sequencing
PCR amplified products were cloned into TopoTA® vector
(In vitrogene, San Diego, CA) and transfected into E. coli.
Cells were grown overnight in terrific broth and Plasmid
DNA was isolated using the SNAP Gel Purification Kit
(Invitrogen, Carlsbad, CA). Samples of plasmid DNA con-
taining inserts of interest were purified using a QIAprep
Spin Plasmid Kit, and then sequenced using ABI PRISM
Big dye Terminator Kit at a commercial facility (Dana Far-
ber Cancer Research Institute, Harvard University, Boston,
MA). The cytb coding region of mitochondrial DNA from
each clone was sequenced five times in both the forward
and reverse direction using the vector primers M13 for-
ward and M13 reverse. DNA and protein sequences align-
ment was performed using the SeqMan™ and MegAlign™
(Seqwright, Houston, TX; DNASTAR, Madison WI) and
MUSCLE [33] protein multiple sequence alignment soft-
wares.  P. falciparum clones 3D7 (Tyr268 allele), K1
(Tyr268 allele) and NGATV0l (Asn268 allele) strain were
used as controls.
Results
A total of 309 samples were obtained from patients in
Nigeria (118), Malawi (93) and Senegal (98). Out these
samples, 295 (Nigeria 111; Malawi 91 and Senegal 93)
were successfully tested for two different mutations on
codon 268 of the parasite's cytb gene, which has been
associated previously with AP treatment failure [12,20,22-
27]. Seven (7), 2 and 3 patient samples from Nigeria,
Malawi and Senegal respectively did not yield PCR prod-
ucts. Patients characteristics are presented in Table 1. All
patients were Africans resident of malaria endemic areas
of West Africa (Nigeria and Senegal) and East Africa
(Malawi) where AP is neither used for chemoprophylaxis
nor for treatment of malaria.
In the parasite populations studied, PCR-RFLP results
revealed no P. falciparum isolate from Nigeria, Senegal or
Malawi with the mutant Ser268 allele in the cytb gene. AllMalaria Journal 2006, 5:82 http://www.malariajournal.com/content/5/1/82
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isolates from Senegal and Malawi harboured the wild-
type cytb Tyr268 allele. In addition, none of the isolates
obtained from these 2 study sites showed the mutant cytb
Asn268 allele.
Surprisingly, five isolates out of the 111 samples obtained
from Nigerian patients showed the mutant cytb Asn268
allele. The resulting pattern after restriction enzyme digest
of some of these five samples is shown in Figure 1. SspI cut
the 174 bp product of the nested PCR into two fragments
(150 bp and 24 bp) in presence of the TAT (Tyr) wild-type
codon, while the mutant AAT (Asn) codon remained
uncut. Fragment sizes between the wild-type cytb Tyr268
and mutant cytb Asn268 differed by 24 bp (Figure 1). One
(1) out of the five (5) samples that revealed the mutant
Asn 268, showed a mixed (Tyr268 and Asn268) pattern,
consisting of wild-type and mutant alleles at codon 268.
The presence of these mutations was further confirmed by
sequencing. Sequencing data (Figure 2) confirmed the
presence of the Asn268 mutation in all the five samples
from which the mutant alleles were detected by RFLP.
Discussion
In this study, the background/baseline prevalence of AP
associated resistance mutations in P. falciparum cytb gene
in isolates from three distinct geographical areas of Africa
where the drug has not been introduced for the treatment
of P. falciparum malaria was determined. The data from
the study provides the very first evidence of the presence
of cytb Tyr268Asn mutation in unexposed P. falciparum
isolates from Africa.
Detection of Asn268 mutation in cytochrome b gene in P. falciparum by Restriction digest method Figure 1
Detection of Asn268 mutation in cytochrome b gene in P. falciparum by Restriction digest method. 174 bp amplification prod-
ucts with the secondary amplification primer pair cytb2/cytb7 (lanes 3, 5, 7, 9) digested with SspI (lanes 2, 4, 6, 8) and were run 
on 2% NuSieve® 3:1 agarose gel. DNA from NGATV01 containing the AAT (Asn) mutation remains uncut (lane 6), while DNA 
from K1 containing the TAT (Tyr) wild-type codon is digested (150 bp) by the enzyme (lane 8). DNA from patient ID011 
showed a mixed infection consisting both the TAT (Tyr) wild-type digested (150 bp) and mutant undigested (174 bp) codons 
(lane 2). Patient ID024 had parasites harboring the mutant (Asn268) allele of cytb as their DNA remained uncut (lane 4) by the 
enzyme. Lanes 1 and 10 represent the low molecular weight DNA ladder (New England Biolabs, Beverly, MA) used as a marker 
for the electrophoresis
150bp
  174bp
           1       2      3       4       5      6       7      8       9      10
Table 1: Characteristics of patients from whom samples were 
used for detection of cytb mutations at codon 268.
Country Number of patients Age range (years)
Nigeria 111 1–12
Malawi 91 0.5–25
Senegal 93 3–70Malaria Journal 2006, 5:82 http://www.malariajournal.com/content/5/1/82
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In 2002, the first case of in vivo resistance to AP was
reported in a non-immune European traveler returning
from Nigeria [22]. Molecular and phenotypic characteri-
zations of the isolate of P. falciparum obtained from the
patient showed a Tyr to Asn mutation at codon 268,
resulting in a 800 fold increase of the IC50 [22]. However,
Fivelman and colleagues [22] argued that since AP combi-
nation is not yet used in West Africa, it is unlikely that the
patient was initially infected with an atovaquone resistant
strain of P. falciparum. Thus, the mutation in the parasites
cytb gene would have occurred under AP pressure. The
data from this study is contradictory to the argument
raised by Fivelman and colleagues [22], since AP combi-
nation is still not used in Nigeria and yet some P. falci-
parum  from the same locality harbor mutant Asn268
allele.
The reasons behind the emergence of the mutant Asn268
allele of cytb gene is indigenous P. falciparum unexposed to
AP combination is remain unclear. It has been suggested
that the mutations at codon 268 of cytb gene in unexposed
P. falciparum populations may occur either naturally [11]
or through prior exposure to related drugs [27]. Trimeth-
oprim-sulfametoxazole is often used for treatment of
Pneumocystis carinii pneumonia in HIV patients in Nigeria.
However, for patients who react to this sulfa-based com-
bination, atovaquone is given as a rescue therapy. It is
possible that treatment with atovaquone in this category
Multiple sequences alignment of cytochrome b gene (residues 137 to 279) of some Nigerian isolates of P. falciparum Figure 2
Multiple sequences alignment of cytochrome b gene (residues 137 to 279) of some Nigerian isolates of P. falciparum. High-
lighted are residues 268 with amino acid changes from the wild-type tyrosine (Y) to the mutant asparagine (N) allele associated 
previously with atovaquone resistance in Plasmodium falciparum. In addition residue 266 in patient ID (Cytb012) where Pro (P) 
is changed to Thr (T) is also highlighted. Sequences of the atovaquone resistant (NGTV01) and sensitive (K1 and 3D7) control 
strains are also present.
Cytb011         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKMPFYPNLL 215 
Cytb012         GYTVSDXTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb014         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb023         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb024         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb027         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb028         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb029         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb038         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb041         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb043         GYTVSDPTLKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb053         GYTVSDPTLKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb053d10      GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb057         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb059         GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
K1F             GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
NGTV01          GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
3D7             GYTVSDPTIKRFFVLHFILPFIGLCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLL 215 
Cytb011         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFNAMLKTVPSKPA 279 
Cytb012         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLTFYAMLKTVPSKPA 279 
Cytb14F         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb023         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb024         SLDVKGFNNVIILFLTQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWHFLPFNAMLKTVPSKPA 279 
Cytb027         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFNAMLKTVPSKPA 279 
Cytb028         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb028         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb038         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFNAMLKTVPSKPA 279 
Cytb041         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb043         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb053         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb053d10      SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFNAMLKTVPSKPA 279 
Cytb057         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
Cytb059         SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
K1              SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 
NGTV01          SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFNAMLKTVPSKPA 279 
3D7             SLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPA 279 Malaria Journal 2006, 5:82 http://www.malariajournal.com/content/5/1/82
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of patients could select for mutant Asn cytb268 in indige-
nous  P. falciparum population in this area where HIV
patients could be co-infected with malaria, although there
is no clear evidence of this selection process. A recent
report [34] has shown that the percentage of individuals
with Pneumocystis carinii pneumonia who are co-infected
with other pathogens is very high (ranging from 20% to
70%) in Africa and other developing countries.
Another potential explanation for the emergence of P. fal-
ciparum with cytb Asn268 mutation in Nigeria could be
due to the selection of this allele by AP in the large
number non-immune (European and Americans) workers
(under AP chemoprophylaxis) in the Nigerian oil indus-
try. Investigations are currently underway to determine if
AP chemoprophylaxis among non-immune oil workers is
exerting some selective pressure on indigenous strains of
P. falciparum.
The detection and confirmation of mutant cytb Asn268
allele in some P. falciparum isolates from Nigeria is a mat-
ter of serious concern since these parasites may spread to
other neighboring African countries where P. falciparum
resistance to atovaquone or AP combination has not been
reported. Recent studies [7,12,22,23] confirmed geneti-
cally and biochemically the linkage of atovaquone/AP
resistance to cytb mutations (Tyr268Ser and Tyr268Asn)
and the molecular mechanisms of parasites resistance this
drugs. Tyr268 is a conserved bulky hydrophobic contact
of atovaquone in the Qo II region of the ubiquinol oxida-
tion site of the cytbc1 complex. Substitution of Tyr268 by
a less bulky Asn268 not only reduces the volume of the
binding pocket, but also decreases the affinity and bind-
ing of atovaquone and thus leads to drug resistance
[22,35]. Of interest, is the presence in one sample
(Cytb012) of an addition mutation at position 266, where
Pro (P) is substituted to Thr (T). The presence and the role
of this mutation within the atovaquone binding site needs
further investigation, as the presence of additional muta-
tions within the ubiquinone reduction site has been pre-
viously suggested to be involved in high level resistance to
the drug [7].
Efforts are currently underway to conduct a more elabo-
rate study where genotypic and phenotypic characteriza-
tion of AP resistant isolates of P. falciparum will be
determined especially in Nigeria.
Conclusion
This study reports for the first time the presence of
Tyr268Asn mutation in unexposed P. falciparum isolates
from Nigeria. The emergence in African P. falciparum iso-
lates of Tyr268Asn mutation which is associated with AP
resistance raises serious concerns about the long-term use
of this drug for malaria chemoprophylaxis in non-
immune travelers visiting West Africa. Continuous moni-
toring of AP resistant P. falciparum in Africa is warranted
for the rational use of this valuable antimalarial drug espe-
cially in non-immune travelers.
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